CAB39 抗体
-
- 抗原 See all CAB39 抗体
- CAB39 (Calcium Binding Protein 39 (CAB39))
-
适用
- 人, 小鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This CAB39 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- 产品特性
- Polyclonal Antibody
- 纯化方法
- Affinity purification
- 免疫原
- Synthetic peptide of human CAB39
- 亚型
- IgG
-
-
- 应用备注
- WB 1:500-1:2000, IHC 1:50-1:200
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1.7 mg/mL
- 缓冲液
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Store at -20°C. Avoid freeze / thaw cycles.
-
- 抗原
- CAB39 (Calcium Binding Protein 39 (CAB39))
- 别名
- CAB39 (CAB39 产品)
- 背景
- Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).
- 分子量
- 40 kDa
- NCBI登录号
- NP_057373
- UniProt
- Q9Y376
- 途径
- AMPK Signaling
-